Although there is evidence of patients with co-occurrence of acute myeloid leukemia (AML) and NSCLC, which achieved complete hematological remission when treated with erlotinib monotherapy (16, 17), subsequent studies evaluating the response of AML patients to EGFR inhibitors alone could not corroborate these findings (18–20). Here, EGFR is linked to non-small cell lung carcinoma.